Longeveron (LGVN) EBT Growth (1y) (2021 - 2026)
Longeveron (LGVN) EBT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | -0.10% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 469.79 Bn | 465.00 Bn | 1.35 Bn | 1,140.26% |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 71.54% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | -8.15% |
| 7 | Belite Bio | 62.62 Bn | 62.62 Bn | - | - |
| 8 | Argenx Se | 56.18 Bn | 50.99 Bn | 1.41 Bn | 88.57% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Longeveron | 15.25 Bn | 15.24 Bn | 264,000.00 | 14.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.64% |
| Dec 31, 2025 | -19.18% |
| Sep 30, 2025 | -80.14% |
| Jun 30, 2025 | -91.97% |
| Mar 31, 2025 | -50.58% |
| Dec 31, 2024 | 4.11% |
| Sep 30, 2024 | 9.51% |
| Jun 30, 2024 | 40.39% |
| Mar 31, 2024 | 89.90% |
| Dec 31, 2023 | -4.63% |
| Sep 30, 2023 | 0.48% |
| Jun 30, 2023 | -20.86% |
| Mar 31, 2023 | -942.87% |
| Dec 31, 2022 | -111.65% |
| Sep 30, 2022 | 76.38% |
| Jun 30, 2022 | 75.46% |
| Mar 31, 2022 | 78.95% |
| Dec 31, 2021 | 3,339.68% |
| Sep 30, 2021 | -2,258.91% |
| Jun 30, 2021 | -1,523.14% |